TIAA CREF Investment Management LLC lowered its holdings in Bio-Techne Corp (NASDAQ:TECH) by 2.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 125,556 shares of the biotechnology company’s stock after selling 2,585 shares during the quarter. TIAA CREF Investment Management LLC owned 0.34% of Bio-Techne Corp worth $14,753,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Teachers Advisors LLC grew its holdings in Bio-Techne Corp by 2.7% in the 2nd quarter. Teachers Advisors LLC now owns 60,303 shares of the biotechnology company’s stock valued at $7,086,000 after buying an additional 1,559 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in Bio-Techne Corp by 89.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,031 shares of the biotechnology company’s stock valued at $356,000 after buying an additional 1,431 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Bio-Techne Corp by 1.5% in the 2nd quarter. Alliancebernstein L.P. now owns 25,784 shares of the biotechnology company’s stock valued at $3,030,000 after buying an additional 390 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Bio-Techne Corp by 7.5% in the 2nd quarter. Wells Fargo & Company MN now owns 49,657 shares of the biotechnology company’s stock valued at $5,834,000 after buying an additional 3,475 shares during the last quarter. Finally, Eaton Vance Management grew its holdings in Bio-Techne Corp by 0.4% in the 2nd quarter. Eaton Vance Management now owns 2,566 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 9 shares during the last quarter. 98.41% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have issued reports on the company. Deutsche Bank AG set a $132.00 target price on Bio-Techne Corp and gave the company a “buy” rating in a report on Wednesday, August 30th. BidaskClub raised Bio-Techne Corp from a “hold” rating to a “buy” rating in a report on Wednesday, August 23rd. Zacks Investment Research lowered Bio-Techne Corp from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. Finally, Wells Fargo & Company assumed coverage on Bio-Techne Corp in a report on Thursday, July 13th. They issued a “market perform” rating on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Bio-Techne Corp presently has a consensus rating of “Buy” and a consensus price target of $127.50.

Shares of Bio-Techne Corp (NASDAQ:TECH) opened at 120.89 on Friday. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of 59.55 and a beta of 0.78. Bio-Techne Corp has a one year low of $95.68 and a one year high of $124.00. The stock’s 50 day moving average price is $119.29 and its 200 day moving average price is $112.20.

Bio-Techne Corp (NASDAQ:TECH) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.99 by $0.10. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. The company had revenue of $156.60 million for the quarter, compared to the consensus estimate of $150.25 million. During the same quarter in the prior year, the business earned $0.92 earnings per share. The firm’s revenue for the quarter was up 16.2% on a year-over-year basis. On average, equities analysts anticipate that Bio-Techne Corp will post $3.99 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 18th were given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 1.06%. The ex-dividend date was Wednesday, August 16th. Bio-Techne Corp’s payout ratio is 65.98%.

In other news, Director Karen A. Holbrook sold 1,059 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $121.73, for a total value of $128,912.07. Following the transaction, the director now owns 914 shares of the company’s stock, valued at $111,261.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 1,359 shares of company stock worth $164,122 in the last ninety days. 3.40% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Bio-Techne Corp (TECH) Shares Sold by TIAA CREF Investment Management LLC” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/01/bio-techne-corp-tech-shares-sold-by-tiaa-cref-investment-management-llc.html.

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.